FFAR4 and type 2 diabetes mellitus: Further studies will examine the oral administration of selective GPR120 agonists which decrease the postprandial blood glucose level immediately before glucose load in a dose-dependent manner, with the ultimate aim of developing drugs for individuals with type 1 as well as type 2 diabetes.